1 Hartmann, K., et al., Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiological reviews, 2016. 96(2):409-447.doi: 10.1152/physrev.00011.2015
2 Mitra, R., Adverse effects of corticosteroids on bone metabolism: a review. PM&R, 2011. 3(5): 466-471.doi: 10.1016/j.pmrj.2011.02.017
3 Botwin, K., et al., Fluoroscopically guided caudal epidural steroid injections in degenerative lumbar spine stenosis. Pain Physician, 2007. 10(4): 547-548.
4 Strehl, C., et al., Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Annals of the rheumatic diseases, 2016. 75(6): 952-957.doi: 10.1136/annrheumdis-2015-208916
5 Van Staa, T., et al., Use of oral corticosteroids and risk of fractures. Journal of bone and mineral research, 2000. 15(6): 993-1000.doi: 10.1359/jbmr.2000.15.6.993
6 Hardy, R. and M. Cooper, Bone loss in inflammatory disorders. Journal of Endocrinology, 2009. 201(3): 309-320.doi: 10.1677/JOE-08-0568
7 van Staa, T.P., et al., Use of oral corticosteroids in the United Kingdom. Qjm, 2000. 93(2): 105-111. doi: 10.1093/qjmed/93.2.105
8 van Staa, T.P., et al., Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res, 2003. 18(5):. 913-918.doi: 10.1359/jbmr.2003.18.5.913
9 Overman, R.A., J.Y. Yeh, and C.L. Deal, Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken), 2013. 65(2):294-298.doi: 10.1002/acr.21796
10 Silverman, S., et al., International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int, 2015. 26(1):419-420.doi: 10.1007/s00198-014-2883-2
11 Fardet, L., I. Petersen, and I. Nazareth, Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford), 2011. 50(11): p. 1982-1990 .doi: 10.1093/rheumatology/ker017
12 Laugesen, K., et al., Systemic glucocorticoid use in Denmark: a population-based prevalence study. BMJ Open, 2017. 7(5): e015237.doi: 10.1136/bmjopen-2016-015237.
13 Tuck, S., et al., Sex steroids and bone turnover markers in men with symptomatic vertebral fractures. Bone, 2008. 43(6):999-1005.. doi: 10.1016/j.bone.2008.08.123.
14 Soen, S. and Y. Tanaka, Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005. 15(3:163-168.doi: 10.1007/s10165-005-0391-0.
15 Dalle Carbonare, L., et al., Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res, 2001. 16(1): 97-103. doi: 10.1359/jbmr.2001.16.1.97.
16 van Staa, T.P., et al., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford), 2000. 39(12):1383138-9. doi: 10.1093/rheumatology/39.
17 Steinbuch, M., T.E. Youket, and S. Cohen, Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int, 2004. 15(4): 323-328. doi: 10.1007/s00198-003-1548-3.
18 Van Staa, T.P., et al., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum, 2003. 48(11): 3224-3229.doi: 10.1002/art.11283.
19 Walsh, L.J., et al., The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med, 2002. 166(5):691-695. doi: 10.1164/rccm.2110047.
20 Van Staa, T.P., et al., Use of oral corticosteroids and risk of fractures. J Bone Miner Res, 2000. 15(6): 993-1000. https://doi.org/10.1002/1099-1557(200009/10)9:5%3C359::AID-PDS507%3E3.0.CO;2-E
21 Yoshioka, T., et al., Steroid receptors in osteoblasts. Clinical Orthopaedics and Related Research (1976-2007), 1980. 148: 297-303.
22 Jilka, R.L., et al., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. The Journal of clinical investigation, 1999. 104(4): p. 439-446 . doi: 10.1172/JCI6610.
23 Gunal, I. and V. Karatosun, Avascular necrosis of the femoral heads after single corticosteroid injection. CMAJ, 2006. 175(1): 31-33. doi: 10.1503/cmaj.051638.
24 Wang, G.J., et al., Femoral head blood flow in long-term steroid therapy: study of rabbit model. South Med J, 1983. 76(12): 1530-1532. doi: 10.1097/00007611-198312000-00018.
25 Drescher, W., et al., Effect of methylprednisolone on reperfusion after femoral head ischemia. Clin Orthop Relat Res, 2002(402): 270-277. doi: 10.1097/00003086-200209000-00027.
26 Wang, Y., et al., Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clin Orthop Relat Res, 2003(410): 213-224. doi: 10.1097/01.blo.0000063602.67412.83.
27 Yin, L., Y.B. Li, and Y.S. Wang, Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J (Engl), 2006. 119(7): 581-588.
28 Li, X., et al., Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int, 2005. 16(1): 101-108. doi: 10.1007/s00198-004-1649-7.
29 Richards, R.N., Short-term corticosteroids and avascular necrosis: medical and legal realities. Cutis, 2007. 80(4): 343-348.
30 Jacobs, B., Epidemiology of traumatic and nontraumatic osteonecrosis. Clin Orthop Relat Res, 1978(130): 51-67.
31 Matsuo, K., et al., Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res, 1988(234): 115-123.
32 Moskal, J.T., R.E. Topping, and L.L. Franklin, Hypercholesterolemia: an association with osteonecrosis of the femoral head. Am J Orthop (Belle Mead NJ), 1997. 26(9): 609-612.
33 Matos, M.A., R.W. Alencar, and S.S. Matos, Avascular necrosis of the femoral head in HIV infected patients. Braz J Infect Dis, 2007. 11(1): 31-34. doi: 10.1590/s1413-86702007000100009.
34 O'Brien, T.J. and G.R. Mack, Multifocal osteonecrosis after short-term high-dose corticosteroid therapy. A case report. Clin Orthop Relat Res, 1992(279): 176-179.
35 Mont, M.A., et al., Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol, 1997. 24(4): 654-662. PMID: 9101497
36 Mok, C.C., C.S. Lau, and R.W. Wong, Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol, 1998. 37(8): p. 895-900. doi: 10.1093/rheumatology/37.8.895.
37 Freeman, H.J. and K.J. Freeman, Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in Crohn's disease. Can J Gastroenterol, 2000. 14(2): 138-143. doi: 10.1155/2000/958086.
38 Hochberg, Z.e., Mechanisms of steroid impairment of growth. Hormone Research, 2002. 58(Suppl. 1): 33-38. doi: 10.1159/000064764.
39 Ohlsson, c., et al., Dexamethasone impairs growth hormone (gh)-stimulated growth by suppressionof local insulin-like growth factor (igf)-i production and expression of gh-and igf-i-receptor in cultured rat chondrocytes. Endocrinology, 1998. 139(7): 3296-3305. doi: 10.1210/endo.139.7.6099.
40 d’Angelo, D.M., et al., Growth and puberty in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021. 19: 1-13. doi: 10.1186/s12969-021-00521-5.
41 Veldhuis, J.D., G. Lizarralde, and A. Iranmanesh, Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. The Journal of Clinical Endocrinology & Metabolism, 1992. 74(1): 96-102.doi: 10.1210/jcem.74.1.1727834.
42 Borges, M.S., et al., IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man. Journal of endocrinological investigation, 1999. 22: 12-17. doi: 10.1007/BF03345472.
43 Jux, C., et al., Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH-and IGF-I-receptor in cultured rat chondrocytes. Endocrinology, 1998. 139(7): 3296-3305..doi: 10.1210/endo.139.7.6099.
44 Silbermann, M. and G. Maor, Mechanisms of glucocorticoid-induced growth retardation: impairment of cartilage mineralization. Cells Tissues Organs, 1978. 101(2): 140-149. doi: 10.1159/000144959.
45 Hahn, T.J., et al., Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. The Journal of Clinical Investigation, 1979. 64(2): 655-665.doi: 10.1172/JCI109506.
46 Altman, A., Z. Hochberg, and M. Silbermann, Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse. Calcified tissue international, 1992. 51: 298-304. doi: 10.1007/BF00334491.
47 Skversky, A.L., et al., Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006. The Journal of Clinical Endocrinology & Metabolism, 2011. 96(12): 3838-3845. doi: 10.1210/jc.2011-1600.
48 Toloza, S., et al., Vitamin D insufficiency in a large female SLE cohort. Lupus, 2010. 19(1): 13-19. doi: 10.1177/0961203309345775.
49 Searing, D.A., et al., Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. Journal of Allergy and Clinical Immunology, 2010. 125(5): 995-1000.doi: 10.1016/j.jaci.2010.03.008.
50 Akeno, N., et al., Regulation of vitamin D-1alpha-hydroxylase and 24-hydroxylase expression by dexamethasone in mouse kidney. Journal of Endocrinology, 2000. 164(3):339-348. doi: 10.1677/joe.0.1640339.
51 Dhawan, P. and S. Christakos, Novel regulation of 25‐hydroxyvitamin D3 24‐hydroxylase (24 (OH) ase) transcription by glucocorticoids: Cooperative effects of the glucocorticoid receptor, C/EBPβ, and the Vitamin D receptor in 24 (OH) ase transcription. Journal of cellular biochemistry, 2010. 110(6): 1314-1323. doi: 10.1002/jcb.22645.
52 Kinoshita, Y., et al., Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone, 2008. 42(1): 226-228.doi: 10.1016/j.bone.2007.09.042.
53 Liamis, G., H.J. Milionis, and M. Elisaf, A review of drug-induced hypocalcemia. Journal of bone and mineral metabolism, 2009. 27: 635-642. doi: 10.1007/s00774-009-0119-x. PMID: 19730969.
54 Shevchuk S, Marynych L, Malovana T, Denyshchych L. Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density. Lupus Sci Med. 2023 Aug;10(2):e000968. doi: 10.1136/lupus-2023-000968. PMID: 37558268; PMCID: PMC10414063.
